S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase

Biochemical and Biophysical Research Communications

Volumn 257, Issue 3, 1999, Pages 657-661

  Barelli, Hélène ^a   Petit, Agnès ^a   Hirsch, Etienne ^b   Wilk, Sherwin ^c   De Nanteuil, Guillaume ^d   Morain, Philippe ^d   Checler, Frédéric ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; AMINOPEPTIDASE B; CALPAIN; CARBOXYLIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; NEUROPEPTIDE; PRESENILIN 1; PRESENILIN 2; PROLYL ENDOPEPTIDASE;

ALZHEIMER DISEASE; ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; LEARNING; MEMORY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SYMPTOMATOLOGY;

EID: 0033590994     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.1999.0366     Document Type: Article

References (28)

1. Hardy J., Allsop D. Trends in Pharmacol. Sci. 12:1991;383-388.
2. Checler F. J. Neurochem. 65:1995;1431-1444.
3. Nitsch R. M. Neurodegeneration. 5:1996;477-482.
4. Husain M. M., Nemeroff C. B. J. Am. Geriatr. Soc. 38:1990;918-925.
5. Checler, F. 1993, in, Methods in Neurotransmitters and Neuropeptides Research. Part 2, 11, 375, 418, Elsevier Science Publishers, Amsterdam.
6. Ishiura S., Tsukahara T., Tabira T., Shimizu T., Arahata K., Sugita H. FEBS Lett. 260:1990;131-134.
7. Shinoda M., Toide K., Ohsawa I., Kohsaka S. Biochem. Biophys. Res. Commun. 235:1997;641-645.
8. Kato A., Fukunari A., Sakai Y., Nakajima T. J. Pharm. Exp. Ther. 283:1997;328-335.
9. Gibson A. M., Edwardson J. A., McDermott J. R. Neurosci. Res. Commun. 9:1991;73-81.
10. Ichai C., Chevallier N., Delaere P., Dournaud P., Epelbaum J., Hauw J. J., Vincent J. P., Checler F. J. Neurochem. 62:1994;645-655.
11. Portevin B., Benoist A., Rémond G., Hervé Y., Vincent M., Lepagnol J., De Nanteuil G. J. Med. Chem. 39:1996;2379-2391.
12. Carpenter, M. B. 1996.
13. Checler F., Vincent J. P., Kitabgi P. J. Biol. Chem. 261:1986;11274-11281.
14. Vincent B., Vincent J. P., Checler F. Brain Res. 709:1996;51-58.
15. Dauch P., Barelli H., Vincent J. P., Checler F. Biochem. J. 280:1991;421-426.
16. Marambaud P., Lopez-Perez E., Wilk S., Checler F. J. Neurochem. 69:1997;2500-2505.
17. Li J., Wilk E., Wilk S. J. Neurochem. 66:1996;2105-2112.
18. Yoshimoto T., Kado K., Matsubara F., Koriyama N., Kaneto H., Tsuru D. J. Pharmacobio. Dyn. 10:1987;730-735.
19. De Nanteuil G., Portevin B., Lepagnol J. Drugs of the Future. 23:1998;167-179.
20. Huston J. P., Hasenöhrl R. U. Behav. Brain Res. 66:1995;117-127.
21. Yoshimoto T., Fischl M., Orlowski R. C., Walter R. J. Biol. Chem. 253:1978;3708-3716.
22. Walter R., Yoshimoto T. Biochemistry. 17:1978;4139-4144.
23. Chevallier N., Jiracek J., Vincent B., Baur C. P., Spillantini M. G., Goedert M., Dive V., Checler F. Brit. J. Pharmacol. 121:1997;556-562.
24. Ancolio K., Marambaud P., Dauch P., Checler F. J. Neurochem. 69:1997;2494-2499.
25. Marambaud P., Alves da Costa C., Ancolio K., Checler F. Biochem. Biophys. Res. Commun. 252:1998;134-138.
26. Hardy J. T.I.N.S. 20:1997;154-159.
27. Schellenberg G. D. Proc. Natl. Acad. Sci. USA. 92:1995;8552-8559.
28. Van Broeckhoven C. Nature Genetics. 11:1995;230-232.